Quantcast

Tag Archives: Pfizer

Mo. class actions over drug expiration dates removable under CAFA

State class actions alleging that drug makers labeled their products with deceptive expiration dates met the amount-in-controversy requirement for removal under the Class Action Fairness Act, the 8th U.S. Circuit Court of Appeals has ruled in reversing judgment.

Read More »

Pfizer must pay $142M over Neurontin marketing

Drug maker Pfizer violated the Racketeer Influenced and Corrupt Organizations Act by engaging in a fraudulent marketing scheme promoting the epilepsy drug Neurontin for “off-label” uses, the 1st U.S. Circuit Court of Appeals has ruled in affirming judgment.

Read More »

Jury awards $5 million in HRT-breast cancer case

A woman who developed breast cancer after taking combination hormone therapy drugs including Premarin, Provera and Prempro for 15 years won a $5 million award against drug companies Wyeth and Upjohn this month.

Read More »

Reglan most litigated drug of 2011, latest ranking says

The anti-nausea drug Reglan and its generic counterparts were the drugs most frequently cited in litigation in 2011, according to a consumer watchdog’s latest analysis of Food and Drug Administration statistics.

Read More »